FLT3 and acute myeloid leukemia: Another phase 2 study, ALLG AMLM16, tested sorafenib in newly diagnosed FLT3-ITD AML, but again, no survival benefit was seen overall, though there were signs of improved outcomes in patients with high VAF and those who underwent allo-HCT in first remission [47].